Home/Pipeline/OncoScreen® Plus (Tissue)

OncoScreen® Plus (Tissue)

Solid Tumor Mutation Profiling

CommercialCE-IVDD Marked

Key Facts

Indication
Solid Tumor Mutation Profiling
Phase
Commercial
Status
CE-IVDD Marked
Company

About Burning Rock Biotech

Burning Rock Biotech's mission is to 'Guard Life via Science' by becoming a new pillar in the international healthcare industry. The company has established itself as a leader in China's precision oncology diagnostics market, with a portfolio of CE-marked kits, a CLIA/CAP-certified lab, and a U.S. FDA Breakthrough Device designation. Its strategy is built on a dual business model of selling IVD products and providing LDT services, while strategically investing in R&D for early cancer detection and a nascent therapeutic pipeline to drive long-term growth.

View full company profile

Therapeutic Areas